Summary of MiNK Therapeutics Q4 2025 Earnings Call

1Key Financial Results and Metrics

Cash Position: Ended 2025 with $13.4 million in cash, up from $4.6 million in 2024. An additional $3 million raised post-year-end through an at-the-market facility.

Net Loss: Q4 2025 net loss was $2.6 million ($0.56 per share), compared to $2.5 million ($0.62 per share) in Q4 2024. Full-year net loss was $12.5 million ($2.93 per share), up from $10.8 million ($2.86 per share) in 2024.

Operational Efficiency: Operating costs decreased nearly 40% year-over-year, reflecting disciplined financial management.

2Strategic Updates and Business Highlights

Clinical Trials: Advancing MiNK cells in Phase II trials for solid tumors and autoimmune conditions, including graft-versus-host disease (GvHD) and severe hypoxemic pneumonia (ARDS).

Clinical Efficacy: Reported median overall survival exceeding 23 months in heavily pretreated cancer patients, with complete remissions extending beyond 2 years.

Funding Strategy: Secured non-dilutive funding from NIH and other sources to support clinical trials, allowing for expansion without increasing capital burden.

New Programs: Initiated a PRAME-targeting iNKT TCR program through the C-Further consortium, aimed at pediatric oncology.

3Forward Guidance and Outlook

2026 Milestones: Expected initiation of randomized Phase II trials for ARDS and GvHD, with initial clinical data anticipated in the second half of 2026.

Scientific Validation: Plans to present multiple data sets and peer-reviewed publications in the first half of 2026 to support ongoing and new clinical programs.

4Bad News, Challenges, or Points of Concern

Increased Net Loss: The rise in net loss year-over-year may raise concerns about the sustainability of current operational spending amidst clinical advancements.

Regulatory and Competitive Risks: The company faces uncertainties related to regulatory approvals and competition in the rapidly evolving cell therapy market.

Dependence on Non-Dilutive Funding: While beneficial, reliance on external funding sources may pose risks if future funding opportunities do not materialize as planned.

5Notable Q&A Insights

Clinical Trial Design: The ARDS trial will use physician's choice as a control arm, with a focus on patients with hypoxemic pneumonia, a population lacking approved therapies.

IPF and GvHD Development: The company is exploring the potential of MiNK cells in idiopathic pulmonary fibrosis (IPF) and GvHD, with plans for separate trials and careful funding considerations.

IL-15 Combination Trials: Clarified that MiNK has not formally announced collaborations related to IL-15 superagonists, emphasizing the importance of transparency in future strategic partnerships. This summary encapsulates the key financial metrics, strategic initiatives, forward-looking statements, challenges, and insights from the Q&A session of MiNK Therapeutics' Q4 2025 earnings call.